ArticleGenes & diseases2026
Neoliensinine promotes lysosomal cell death in T cell malignancies via a novel STING-TUBA1B pathway.
Article in Genes & diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical treatment options for T cell malignancies (T-CMs) remain limited, and even the current popular immunotherapies have yet to demonstrate significant efficacy in addressing this disease. Identifying effective therapeutic targets for T-CMs and developing corresponding drugs are still critical goals in this field. Stimulator of interferon genes (STING) is highly expressed in T cells and plays a pivotal role in T cell immunity. However, the mechanisms underlying STING-mediated cell death are not well understood. Neoliensinine (NeoL), a unique bisbenzylisoquinoline alkaloid from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.